NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple ...

ROCHESTER, NY, May 2, 2024 – Empire Discovery Institute (EDI) has entered into a collaborative research partnership with the National Multiple Sclerosis Society and its commercial development program ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave, a leading digital health sciences company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today ...

Partial sales of TG Therapeutics, Inc.'s BRIUMVI for Relapsing forms of multiple sclerosis reached $7.8 million in Q1 of 2023. In June 2023, TG Therapeutics received European approval of BRIUMVI for ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that ZEPOSIA® (ozanimod) 0.92 mg, a new once-daily oral medication for adults for the treatment of relapsing forms ...

HIGH POINT, N.C.--(BUSINESS WIRE)--Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, today announced that BAFIERTAM™ (monomethyl fumarate), a novel fumarate for ...